CY1124527T1 - Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση - Google Patents

Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση

Info

Publication number
CY1124527T1
CY1124527T1 CY20211100851T CY211100851T CY1124527T1 CY 1124527 T1 CY1124527 T1 CY 1124527T1 CY 20211100851 T CY20211100851 T CY 20211100851T CY 211100851 T CY211100851 T CY 211100851T CY 1124527 T1 CY1124527 T1 CY 1124527T1
Authority
CY
Cyprus
Prior art keywords
pi3k
intravenous administration
mtor inhibitor
inhibitor preparation
phenyl
Prior art date
Application number
CY20211100851T
Other languages
Greek (el)
English (en)
Inventor
Kevin Richard Back
Michael Cram
Aidan James Harper
James W. Huang
Jonathan Richard Lillis
Timothy Michael Lukas
Sumit Luthra
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of CY1124527T1 publication Critical patent/CY1124527T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20211100851T 2014-12-17 2021-09-28 Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση CY1124527T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093060P 2014-12-17 2014-12-17
US201562250633P 2015-11-04 2015-11-04
PCT/IB2015/059515 WO2016097949A1 (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Publications (1)

Publication Number Publication Date
CY1124527T1 true CY1124527T1 (el) 2022-07-22

Family

ID=54937330

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100851T CY1124527T1 (el) 2014-12-17 2021-09-28 Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση

Country Status (25)

Country Link
US (2) US10172942B2 (cg-RX-API-DMAC7.html)
EP (1) EP3233054B1 (cg-RX-API-DMAC7.html)
JP (1) JP6420753B2 (cg-RX-API-DMAC7.html)
KR (1) KR102016822B1 (cg-RX-API-DMAC7.html)
CN (1) CN107205923B (cg-RX-API-DMAC7.html)
AU (1) AU2015365497B2 (cg-RX-API-DMAC7.html)
CA (1) CA2915199C (cg-RX-API-DMAC7.html)
CY (1) CY1124527T1 (cg-RX-API-DMAC7.html)
DK (1) DK3233054T3 (cg-RX-API-DMAC7.html)
ES (1) ES2881214T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211446T1 (cg-RX-API-DMAC7.html)
HU (1) HUE055928T2 (cg-RX-API-DMAC7.html)
IL (1) IL252158B (cg-RX-API-DMAC7.html)
LT (1) LT3233054T (cg-RX-API-DMAC7.html)
MX (1) MX380172B (cg-RX-API-DMAC7.html)
NZ (1) NZ731518A (cg-RX-API-DMAC7.html)
PL (1) PL3233054T3 (cg-RX-API-DMAC7.html)
PT (1) PT3233054T (cg-RX-API-DMAC7.html)
RS (1) RS62337B1 (cg-RX-API-DMAC7.html)
RU (1) RU2672875C1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703826TA (cg-RX-API-DMAC7.html)
SI (1) SI3233054T1 (cg-RX-API-DMAC7.html)
TW (1) TWI660729B (cg-RX-API-DMAC7.html)
WO (1) WO2016097949A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703764B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
US12109308B2 (en) * 2018-06-07 2024-10-08 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
KR20240040768A (ko) 2021-07-26 2024-03-28 셀퀴티 인크. 암의 치료에 사용하기 위한 1-(4-{[4-(디메틸아미노)피페리딘-1-일]카르보닐}페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물
WO2025128712A1 (en) 2023-12-12 2025-06-19 Celcuity Inc. Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2006251429A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DE202008001253U1 (de) * 2008-01-28 2008-04-10 Mirror Image Ag Bildanzeigegerät
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US9757432B2 (en) * 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
JP6309610B2 (ja) * 2013-03-14 2018-04-11 アブラクシス バイオサイエンス, エルエルシー 膀胱がんを処置する方法
EP3116547B1 (en) * 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Also Published As

Publication number Publication date
RU2672875C1 (ru) 2018-11-20
SG11201703826TA (en) 2017-07-28
JP6420753B2 (ja) 2018-11-07
RS62337B1 (sr) 2021-10-29
US20190105390A1 (en) 2019-04-11
MX380172B (es) 2025-03-12
SI3233054T1 (sl) 2021-11-30
HRP20211446T1 (hr) 2021-12-24
US20170360935A1 (en) 2017-12-21
JP2016113461A (ja) 2016-06-23
DK3233054T3 (da) 2021-08-02
PT3233054T (pt) 2021-08-02
AU2015365497A1 (en) 2017-06-01
TW201632188A (zh) 2016-09-16
WO2016097949A1 (en) 2016-06-23
BR112017010841A2 (pt) 2017-12-26
AU2015365497B2 (en) 2020-07-02
PL3233054T3 (pl) 2021-12-20
HUE055928T2 (hu) 2022-01-28
KR102016822B1 (ko) 2019-08-30
EP3233054A1 (en) 2017-10-25
LT3233054T (lt) 2021-07-26
CA2915199C (en) 2018-11-06
KR20170082638A (ko) 2017-07-14
US10172942B2 (en) 2019-01-08
CN107205923B (zh) 2021-03-05
US10660959B2 (en) 2020-05-26
EP3233054B1 (en) 2021-06-30
IL252158A0 (en) 2017-07-31
CN107205923A (zh) 2017-09-26
MX2017008072A (es) 2017-09-28
NZ731518A (en) 2019-03-29
CA2915199A1 (en) 2016-06-17
TWI660729B (zh) 2019-06-01
ZA201703764B (en) 2020-11-25
ES2881214T3 (es) 2021-11-29
IL252158B (en) 2021-01-31

Similar Documents

Publication Publication Date Title
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
CY1122078T1 (el) Θεραπευτικα νανοσωματιδια που εμπεριεχουν θεραπευτικο παραγοντα και μεθοδοι παρασκευης και χρησης αυτων
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
CL2017001061A1 (es) Cromanos sustituidos y métodos para su uso
MX391812B (es) Agonista fxr derivado de esteroides.
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
UY38712A (es) Lactamas fusionadas de arilo y heteroarilo
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
EA201792116A1 (ru) Ингибитор янус-киназы
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CY1124820T1 (el) Φαρμακευτικο υδατικο σκευασμα που περιλαμβανει 1-(4-{[4-(διμεθυλαμινο)πιπεριδιν-1-υλ]καρβονυλ}φαινυλ)-3[4-(4,6-διμορφολιν-4-υλ-1,3,5-τριαζιν-2-υλ)φαινυλ]ουρια
CY1123576T1 (el) Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
MX379245B (es) Compuesto de tres ciclos y aplicaciones del mismo
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
MX2016015856A (es) Derivados de naftiridinadiona.
MX386761B (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo.
EA201692298A1 (ru) Производные карбоксамидов